期刊文献+

浸润性乳腺癌中CRABPⅡ和E-FABP的差异表达及与临床病理的关系 被引量:1

The relationship of different expressions of cellular retinoic acid-binding protein Ⅱ and epidermal fatty acid-binding protein with the clinical pathology in the invasive breast cancer
下载PDF
导出
摘要 目的 :探讨细胞视黄酸结合蛋白(cellular retinoic acid-binding proteinⅡ,CRABPⅡ)和表皮脂肪酸结合蛋白(epidermal fatty acid-binding protein,E-FABP)的差异表达在乳腺癌中的意义,以及与临床病理特征和分型的关系。方法:分析123例浸润性乳腺癌患者的临床资料,采用免疫组化法检测乳腺癌组织中CRABPⅡ和E-FABP的表达。结果:CRABPⅡ和E-FABP在浸润性乳腺癌的表达存在显著差异(P<0.01)。此差异表达分为E-FABP≥CRABPⅡ与E-FABP﹤CRABPⅡ两种。在浸润性乳腺癌中,E-FABP≥CRABPⅡ的表达较多见。CRABPⅡ和E-FABP的差异表达与腋窝淋巴结转移和TNM分期有关(P<0.05)。差异表达与病理分型相关,Luminal A型中E-FABP≥CRABPⅡ的百分率最低(61.6%),Basal-like型中的百分率最高(95.2%)。结论 :在浸润性乳腺癌中,CRABPⅡ和E-FABP的差异表达可能与乳腺癌的侵袭性及预后相关,E-FABP≥CRABPⅡ时的乳腺癌侵袭性高、预后差。 Objective:To explore the signiifcance of the different expressions of cellular retinoic acid-binding proteinⅡ(CRABP Ⅱ ) and epidermal fatty acid-binding protein (E-FABP) in the breast cancer and the relationship of their clinical pathological features and types. Methods: The clinical data on 123 cases with invasive breast cancer were analyzed and the expressions of CRABP Ⅱand E-FABP were detected by immunohistochemistry in the breast cancer tissues. Results:There existed different expressions between CRAB Ⅱand E-FABP in the invasive breast cancer (P〈0.01), which could be classiifed into two types of E-FABP≥CRABP Ⅱand E-FABP〈CRABPⅡ. The expression of E-FABP≥CRABP II was seen more in the invasive breast cancer. The different expressions of CRABP II and E-FABP were related to axillary lymph node metastasis and TNM staging. Different expression was related to pathological types. The percentage rate of E-FABP≥CRABPⅡwas the lowest in Luminal A subtype (61.1%) and the highest (95.2%) in Basal-like type. Conclusions:In the invasive breast cancer the different expressions of CRABP Ⅱand E-FABP may have the relationship with the invasion and prognosis of the breast cancer. When E-FABP is ≥CRABPⅡ, the breast cancer has higher invasion and its prognosis is poor.
出处 《上海医药》 CAS 2014年第10期20-23,45,共5页 Shanghai Medical & Pharmaceutical Journal
基金 上海青年医师培养资助计划(沪卫人事[2012]105号)
关键词 浸润性乳腺癌 细胞视黄酸结合蛋白 表皮脂肪酸结合蛋白 临床病理特征 病理分型 invasive breast cancer retinoic acid-binding protein II epidermal fatty acid-binding protein clinical pathological feature pathological types
  • 相关文献

参考文献17

  • 1郑莹,吴春晓,张敏璐.乳腺癌在中国的流行状况和疾病特征[J].中国癌症杂志,2013,23(8):561-569. 被引量:848
  • 2Donato L J, Noy N. Suppression of mammary carcinoma growth by retinoic acid proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein 1I signaling[J]. Cancer Res, 2005, 65(18): 8193-8199.
  • 3李华,吕青,薛晖,董立华,SaimaNaz,羊惠君.表皮型脂肪酸结合蛋白和脂肪酸合成酶在乳腺浸润性导管癌的表达及临床病理意义[J].南方医科大学学报,2008,28(3):381-384. 被引量:6
  • 4Liu RZ, Graham K, Glubrecht DD, et al. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy[J]. Am J Pathol, 2011, 178(3): 997-1008.
  • 5齐晓伟,姜军.2012年第4版《WHO乳腺肿瘤组织学分类》介绍[J].中华乳腺病杂志(电子版),2012,6(5):62-64. 被引量:46
  • 6刘倩,吴宁,孟红,丁兀兀,何小艳,易瑛.乳腺浸润性导管癌中CRABPⅡ和E-FABP的表达及其意义[J].临床与实验病理学杂志,2013,29(9):953-957. 被引量:4
  • 7Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28(16): 2784-2795.
  • 8Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. Arch Pathol Lab Med, 2007, 131(1): 18-43.
  • 9乳腺癌HER2检测指南(2009版)[J].中华病理学杂志,2009,38(12):836-840. 被引量:193
  • 10Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011, 22(8): 1736-1747.

二级参考文献95

  • 1王启俊,祝伟星,邢秀梅.北京城区女性乳腺癌发病死亡和生存情况20年监测分析[J].中华肿瘤杂志,2006,28(3):208-210. 被引量:81
  • 2汤参娥,李萃,肖志强,章晓鹏,陈主初,易红,李建玲,段朝军,梁宋平.人肺鳞癌组织的比较蛋白质组学研究[J].中华肿瘤杂志,2006,28(4):274-279. 被引量:14
  • 3陈建国,朱健,张永辉.启东市1972~2000年主要恶性肿瘤生存率分析[J].中国肿瘤,2006,15(9):575-578. 被引量:33
  • 4<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 5Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312.
  • 6Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145.
  • 7Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487.
  • 8Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497.
  • 9Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25.
  • 10Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102.

共引文献1089

同被引文献15

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部